Core Viewpoint - Moderna Inc. is experiencing a resurgence in stock momentum after a significant decline since its peak in 2021, driven by improved financial outlook and investor sentiment [1][4]. Group 1: Stock Performance - The stock has seen a 91.87% decline from its all-time high in 2021, but has recently gained 76% from its November 2025 lows [1][3]. - The Momentum score in Benzinga's Edge Stock Rankings has increased from 22.5 to 74.61 in just one week, indicating a strong turnaround in investor sentiment [2][3]. - Shares have climbed 31.7% in the past month and an additional 14.8% over the past week [3]. Group 2: Financial Outlook - Moderna's full-year 2025 revenue is projected at $1.9 billion, exceeding previous estimates by approximately $100 million [4]. - The company has reduced its GAAP operating expense forecast by about $200 million for the year, improving its cost structure [4]. - The projected year-end cash balance has been increased to $8.1 billion, contributing to positive investor sentiment [4]. Group 3: Recent Trading Activity - On a recent trading day, shares of Moderna closed down 3.01% at $39.36 but were up 0.66% overnight [5]. - The stock maintains a favorable price trend across short, medium, and long-term time frames in Benzinga's Edge Stock Rankings [5].

Core Insights - Moderna's shares increased by 13% following the announcement of preliminary sales for 2025 and business outlook for 2026 and beyond [2] - The company reported unaudited total revenues of $1.9 billion for 2025, exceeding the previous guidance range of $1.6-$2.0 billion [3] - Moderna expects operating expenses for 2025 to be between $5.0 billion and $5.2 billion, lower than the prior guidance of $5.2-$5.4 billion [3] Financial Performance - Moderna anticipates ending 2025 with cash and cash equivalents of $8.1 billion, an increase from the previous forecast of $6.5-$7.0 billion [4] - The company projects up to 10% revenue growth for 2026, with targeted operating expenses of approximately $4.9 billion [4] - For 2027, while no revenue guidance was provided, operating expenses are expected to be in the range of $4.2-$4.7 billion [5] Stock Performance - Year-to-date, Moderna's shares have risen by 20%, compared to the industry's growth of 19% [6] Pipeline and Milestones - Moderna has over 30 mRNA-based investigational candidates in various clinical stages, targeting multiple indications including cancer [9] - The company submitted regulatory filings for its seasonal influenza vaccine mRNA-1010 in several regions, with expectations for approval this year but a commercial launch anticipated next year [10] - Data readouts from late-stage studies on RSV and norovirus vaccines are expected before the end of this year [12] Oncology Focus - A key candidate in Moderna's pipeline is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, with a commercial launch targeted for next year [13] - Moderna is expanding its oncology pipeline, prioritizing the development of mRNA-4359, with a data readout expected before the end of 2026 [14]

Economic Policy and Market Reactions - Trump announced a 25% tax on imports from countries doing business with Iran, coinciding with protests in Iran resulting in over 2,500 deaths [1] - U.S. companies face pressure to deliver strong profit growth, with analysts expecting S&P 500 companies to report an 8.3% increase in earnings per share for Q4 2025 compared to the previous year [2] - The U.S. stock market is set for a low opening, with Dow futures down 0.21%, S&P 500 e-mini futures down 0.16%, and Nasdaq 100 futures down 0.17% [11] Company Performance - JPMorgan Chase reported weaker profit and revenue than expected, leading to a 4.2% drop in its stock, significantly impacting the market [3] - Moderna's stock surged 17.1% after announcing expected revenue for 2025 above previous forecasts, along with updates on new products including a seasonal flu vaccine [7] Bond Market and Interest Rates - Treasury yields eased following an inflation update that met economists' expectations, reinforcing predictions of at least two interest rate cuts by the Federal Reserve in 2026 [8] - The 10-year Treasury yield decreased to 4.17% from 4.19%, while the two-year Treasury yield fell to 3.52% from 3.54% [10][12] Inflation and Consumer Prices - U.S. consumer prices rose 2.7% year-over-year, slightly above expectations and exceeding the Federal Reserve's 2% inflation target [9][12]

Market Overview - On January 13, US stock markets closed lower across the board, with the financial sector experiencing significant declines, impacting overall market performance [1][4][6] - The Dow Jones Industrial Average fell by 0.8% to close at 49,191.99 points, while the S&P 500 and Nasdaq indices dropped by 0.19% and 0.1%, closing at 6,963.74 and 23,709.87 points respectively [4][6] Financial Sector Performance - The financial sector saw a substantial drop, led by JPMorgan Chase, which fell over 4%. Other major financial stocks like Morgan Stanley, Goldman Sachs, Citigroup, Bank of America, and Wells Fargo also experienced declines of over 1% [6][7] - Visa's stock dropped more than 4%, with an intraday decline exceeding 5% [6] Technology Sector Performance - Major tech stocks showed mixed results, with Google rising over 1% while companies like Meta, Amazon, and Microsoft fell by more than 1%. Nvidia and Apple had gains of less than 1% [8] - The Philadelphia Semiconductor Index increased by 0.95%, reaching a new historical high, with notable gains from Intel (over 7%) and AMD (over 6%) [8] Energy Sector Performance - Energy stocks collectively rose, with ExxonMobil increasing by nearly 2% and other companies like Schlumberger and Occidental Petroleum rising over 1% [9] Precious Metals Market - The international silver price reached a new historical high, surpassing $89 per ounce, with an increase of over 2% on January 13. Since the beginning of 2026, the price has risen by more than 20% in less than 10 trading days [14][15] Chinese Concept Stocks - Chinese concept stocks generally declined, with the Nasdaq Golden Dragon China Index dropping by 1.86%. Notable declines included Brain Rebirth (over 26%) and WeRide (over 10%) [12][13] - However, some stocks like Canadian Solar and BeiGene saw gains of over 5% [13]

Core Insights - Moderna, Inc. has experienced a significant decline in total revenue from 2023 to date, primarily attributed to the waning demand for its COVID-19 vaccine, SpikeVax [1] Company Overview - Moderna is known for the successful development and commercialization of its COVID-19 vaccine, SpikeVax, which has been a key driver of its revenue in previous years [1] Financial Performance - The company has reported a sharp decline in total revenue, indicating potential challenges in sustaining its financial performance post-pandemic [1]

Core Viewpoint - Moderna is focused on building a respiratory vaccine franchise to generate cash for investment in oncology and rare disease assets [2] Group 1: Product Development - Moderna has three products approved by the FDA and globally [2] - Two products have been submitted for regulatory approval, specifically flu and flu plus COVID [2] - Norovirus vaccine is currently in Phase III trials [2] Group 2: Future Pipeline - The company has an exciting oncology pipeline with multiple catalysts expected in 2026 [2]

Summary of Moderna's Presentation at the JPMorgan Healthcare Conference Company Overview - **Company**: Moderna - **Event**: 44th Annual JPMorgan Healthcare Conference - **CEO**: Stéphane Bancel Key Points Industry and Company Strategy - Moderna aims to build a respiratory vaccine franchise to generate cash for investments in oncology and rare disease assets [2][3] - The company has three FDA-approved products and two products submitted for regulatory approval (flu and flu plus COVID) [2][3] - A focus on diversifying away from COVID-19 vaccines to ensure future growth [3] Financial Performance - Sales guidance for 2025 was initially $1.62 billion, but the company expects to achieve around $1.9 billion, exceeding the midpoint of the range by $100 million [3] - Cash costs have been significantly reduced from $6.3 billion in 2024 to an expected $4.3-$4.5 billion by the end of 2025, a reduction of nearly $2 billion [5][6] - The company ended 2025 with a cash balance of $8.1 billion, including a credit facility providing liquidity of $9 billion [7] Growth Drivers - **Geographic Diversification**: Partnerships in the U.K., Canada, and Australia to build dedicated factories, ensuring long-term volume commitments [8] - **New Product Launches**: Introduction of mRESVIA, a higher efficacy COVID vaccine, which has achieved a 24% market share in retail and 32% in the elderly segment [9] - Anticipation of re-entering the European market for COVID vaccines post-2026 due to the expiration of Pfizer's partnership with the EU [10][11] Pipeline and R&D - A robust oncology pipeline with 10 clinical studies ongoing for mRNA-4157 combined with Keytruda, including three phase three studies [14][15] - Potential for significant breakthroughs in oncology with mRNA-4359 and mRNA-2808, targeting metastatic settings and multiple myeloma, respectively [15][37] - Upcoming readouts expected in 2026 for various oncology products, including phase three data for mRNA-4157 [18][23] Market Dynamics - The company anticipates a potential sales growth of up to 10% in 2026, driven by both U.S. and international markets [38] - The U.S. market is experiencing a decrease in COVID vaccine volume, but the introduction of new products and partnerships is expected to stabilize sales [39][40] - The flu vaccine (mRNA-1010) is expected to launch in 2027, with minimal sales anticipated in 2026 due to regulatory timelines [44][45] Cost Management and Profitability - Continued focus on cost discipline to achieve cash break-even by 2028, with a reduction in R&D costs as existing phase three commitments sunset [21][22] - Gross margin improvements expected through increased volume, productivity enhancements, and internal manufacturing capabilities [50][51] Conclusion - Moderna is positioned for growth through strategic diversification, innovative product launches, and effective cost management, with a strong focus on oncology and respiratory vaccines as key areas for future development [22][25]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - Moderna reiterates its expectations for revenue growth of up to 10% in 2026 [1] Company Summary - The company is projecting a revenue increase of up to 10% by the year 2026 [1]

Core Viewpoint - Moderna expects to report approximately $1.9 billion in sales for 2025, which is near the upper end of its previously projected range of $1.6 billion to $2 billion, but significantly lower than revenue levels achieved during the COVID-19 pandemic [1] Financial Projections - The projected sales for 2025 are positioned at $1.9 billion, indicating a strong outlook within the previously set forecast range [1] - The anticipated revenue remains well below the peak levels experienced during the COVID-19 pandemic, highlighting a shift in market dynamics [1]